Preparation of Grant Application for a Clinical Phase Ib Trial with NeuroRestore ACD856

3M kr SEK

Funder	Vinnova
Recipient Organization	Alzecure Pharma Ab
Country	Sweden
Start Date	Oct 11, 2023
End Date	Oct 03, 2024
Duration	358 days
Number of Grantees	2
Roles	Principal Investigator
Data Source	Swedish Research Council
Grant ID	`2023-03029_Vinnova`

Grant Description

Purpose and goal:

The goal of this preparatory project, which was to compile a competitive grant application to the European Innovation Council (EIC) in order to conduct a clinical study with the innovative drug candidate NeuroRestore ACD856, was completed according to plan. The grant application was submitted in October 2024.

Expected results and effects:

If the project is awarded a grant from the EIC, the planned clinical study with NeuroRestore ACD856 will be carried out, which may lead to a new drug candidate becoming available for patients with Alzheimer´s disease in the future. Approach and implementation:

The team first submitted a so-called “step 1” proposal to the EIC which was written to assess whether the project fitted the EIC programme objectives. After the project was approved in stage 1, work began on the significantly more comprehensive proposal for stage 2. The application material was created and carefully worked through within the project team and in collaboration with several external experts.